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ABSTRACT
Apatinib is a new oral antiangiogenic molecule that inhibits vascular
endothelial growth factor receptor-2. The present study aimed to
determine the metabolism, pharmacokinetics, and excretion of
apatinib in humans and to identify the enzymes responsible for its
metabolism. The primary routes of apatinib biotransformation inclu-
ded E- and Z-cyclopentyl-3-hydroxylation, N-dealkylation, pyridyl-25-
N-oxidation, 16-hydroxylation, dioxygenation, and O-glucuronidation
after 3-hydroxylation. Nine major metabolites were confirmed by
comparison with reference standards. The total recovery of the
administered dose was 76.8% within 96 hours postdose, with 69.8
and 7.02% of the administered dose excreted in feces and urine,
respectively. About 59.0% of the administered dose was excreted
unchanged via feces. Unchanged apatinib was detected in
negligible quantities in urine, indicating that systemically avail-
able apatinib was extensively metabolized. The major circulating
metabolite was the pharmacologically inactive E-3-hydroxy-apatinib-
O-glucuronide (M9-2), the steady-state exposure of which was
125% that of the apatinib. The steady-state exposures of E-3-
hydroxy-apatinib (M1-1), Z-3-hydroxy-apatinib (M1-2), and apatinib-
25-N-oxide (M1-6) were 56, 22, and 32% of parent drug exposure,
respectively. Calculated as pharmacological activity index values,
the contribution of M1-1 to the pharmacology of the drug was 5.42
to 19.3% that of the parent drug. The contribution of M1-2 and M1-6
to the pharmacology of the drug was less than 1%. Therefore,
apatinib was a major contributor to the overall pharmacological
activity in humans. Apatinib was metabolized primarily by CYP3A4/
5 and, to a lesser extent, by CYP2D6, CYP2C9, and CYP2E1.
UGT2B7 was the main enzyme responsible for M9-2 formation.
Both UGT1A4 and UGT2B7 were responsible for Z-3-hydroxy-
apatinib-O-glucuronide (M9-1) formation.
Introduction
New blood vessel formation (angiogenesis) is a critical step for
tumor cell survival, proliferation, local invasion, and metastasis
(Carmeliet and Jain, 2000). Vascular endothelial growth factor
receptors (VEGFRs) are receptor tyrosine kinases (RTKs) that function
as key regulators of this process. The VEGFR-family proteins consist
of three members: VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and
VEGFR-3 (Flt-4), among which VEGFR-2 is thought to be principally
responsible for angiogenesis in malignancies (Glade-Bender et al.,
2003). Small-molecule VEGFR inhibitors are widely used for the
treatment of metastatic renal cell carcinoma, gastrointestinal stromal
tumors, hepatocellular carcinoma (Ivy et al., 2009), soft tissue sarcoma
(Gennigens and Jerusalem, 2012), and medullary thyroid cancer
(Degrauwe et al., 2012) and in the development of a number of other
oncology indications, including colorectal cancer, non-small-cell lung
cancer, pancreatic cancer, ovarian cancer, and breast cancer (Ivy et al.,
2009).
Apatinib (N-[4-(1-cyano-cyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-
3-pyridine carboxamide, formerly known as YN968D1) is an orally
administered small-molecule RTK inhibitor that selectively targets
VEGFR-2 with an IC50 of approximately 1 nM. Apatinib also less
effectively inhibits the activities of platelet-derived growth factor-b
(PDGFR-b), c-kit, and c-src, all of which have been implicated in the
pathogenesis of human tumors (Irby and Yeatman, 2000; Heinrich
et al., 2002; Song et al., 2005). Apatinib shows antitumor efficacy, with
good tolerance, in mice when administered alone or in combination
with chemotherapeutic drugs against a broad range of human tumor
xenografts (Tian et al., 2011).
Apatinib reverses P-glycoprotein (ABCB1)- and ABCG2-mediated
multidrug resistance in drug-resistant solid tumor cells by inhibiting
their transport function (Mi et al., 2010). It also targets to side pop-
ulation cells and ABCB1-overexpressing leukemia cells to enhance
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the efficacy of chemotherapeutic drugs (Tong et al., 2012). These results
suggest that apatinib may be used in combination with conventional
ABCB1 and ABCG2 substrate chemotherapeutic drugs to overcome
multidrug resistance in clinical cancer chemotherapy.
The results from a phase 1 clinical study conducted in patients with
advanced solid tumors have shown that apatinib can be well tolerated
and exhibits substantial antitumor activity across a broad range of
malignancies at the recommended dose of 750 mg once daily (Li et al.,
2010). The pharmacokinetic parameters of apatinib in plasma were
also calculated using noncompartmental analysis. Apatinib is currently
being evaluated in phase 2/3 clinical trials for the treatment of many
advanced cancer types, including gastric carcinoma, hepatocellular
carcinoma, breast cancer, and colorectal cancer.
Absorption, distribution, metabolism, and excretion studies have
become an integral and critical part of drug development. The present
study was undertaken to assess the metabolic profile, routes of ex-
cretion, and pharmacokinetics of apatinib in humans after single- or
multiple-dose administration of 750 mg of apatinib mesylate tablets
(corresponding to 604 mg of apatinib free base). Cytochrome P450
(P450) isozymes responsible for the oxidative metabolism of apatinib,
as well as UDP-glucuronosyltransferase (UGT) isozymes involved in
the O-glucuronidation of hydroxylated metabolites of apatinib, were




Apatinib mesylate tablets were manufactured by Jiangsu Hengrui Medi-
cine Co., Ltd. (Lianyungang, China) and used for clinical trials. Reference
standards of apatinib mesylate, E-3-hydroxy-apatinib (M1-1), Z-3-hydroxy-
apatinib (M1-2), and vatalanib (internal standard for pharmacokinetic study)
were also provided by Hengrui Medicine. The reference standard of
apatinib-25-N-oxide (M1-6) was synthesized and purified in our laboratory.
Reference standards of Z-3-hydroxy-16-hydroxy-N-dealkylated metabolite
(M4-7), E-3-hydroxy-16-hydroxy-N-dealkylated metabolite (M4-8), Z-3-hydroxy-
25-N-oxide metabolite (M6-9), E-3-hydroxy-25-N-oxide metabolite (M6-10),
E-3-hydroxy-O-glucuronide-N-dealkylated metabolite (M8-2), and E-3-hydroxy-
apatinib-O-glucuronide (M9-2) were isolated and purified from human urine
in our laboratory. The following chemicals were purchased from Sigma-Aldrich
(St. Louis, MO): NADPH, alamethicin, uridine 59-diphosphoglucuronic acid
(UDPGA), b-glucuronidase from Helix pomatia (type H-3), 1-aminobenzo-
triazole (ABT), sulfaphenazole, ticlopidine, quinidine, ketoconazole, chlormethia-
zole, racemic flurbiprofen, mefenamic acid, hecogenin, and all high-performance
liquid chromatography (HPLC)-grade solvents used for ultra performance
liquid chromatography-UV/quadrupole time-of-flight mass spectrometry
(UPLC-UV/Q-TOF MS) and liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) analysis. Other reagents used were of analytical
grade (Sinopharm Chemical Reagent Co. Ltd, Shanghai, China). Deionized
water was purified by a Millipore Milli-Q Gradient Water Purification System
(Molsheim, France). YMC*GEL ODS-A-HG (12 nm S-50 mM; YMC Co.
Ltd., Kyoto, Japan) was used to fractionate the urine samples before further
purification.
Enzyme Sources
Pooled human liver microsomes (HLMs), recombinant human P450
isozymes (CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C9,
CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, and CYP4A11), recombi-
nant human flavin-containing mono-oxygenases (FMO1, FMO3, and FMO5),
and recombinant human UGTs (UGT1A1, UGT1A3, UGT1A4, UGT1A6,
UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15,
and UGT2B17) were purchased from BD Gentest (Woburn, MA). Pooled
human intestinal microsomes (HIMs), human pulmonary microsomes (HPMs),
and human renal microsomes (HRMs) were purchased from Xenotech LLC
(Lenexa, KS).
Study Design, Dosing, and Sample Collection
Human studies were conducted in accordance with the principles of the
Declaration of Helsinki and Good Clinical Practice. Written informed consent
was obtained from all subjects before enrollment.
Healthy Subject Study. This was a single-center, nonrandomized, open-
label study. The study protocol and informed consent document were approved
by the Ethics Committee of Teda International Cardiovascular Hospital
(Tianjin, China). Twelve (six men, six women) healthy Chinese subjects with
a mean age of 25.6 years (range, 21–29 years) and a mean body mass index of
22.3 kg/m2 (range, 19.8–24.0 kg/m2) participated in the study. The subjects
were in good health as assessed by physical examination, without histories of
drug or alcohol abuse; they were nonsmokers and on no other medication at the
time of the study. After at least a 10-hour overnight fast, each subject received
a single dose of 750 mg of apatinib mesylate tablets (corresponding to 604 mg
of apatinib free base). Urine samples were collected at predose and between
0–4, 4–8, 8–12, 12–24, 24–36, 36–48, 48–72, and 72–96 hours after dosing and
stored at 270°C until analysis. Fecal samples were collected at predose and
after each bowel movement for up to 96 hours postdose and homogenized with
5 volumes of methanol. The fecal homogenates were stored at 270°C until
analysis.
Patient Study. This was a single-center, nonrandomized, open-label study.
The study protocol was approved by the Ethics Committee of Fudan University
Shanghai Cancer Center (Shanghai, China). Patients with histologically
confirmed advanced colorectal cancer for which no standard curative therapy
was available were eligible for this study. Patient entry criteria included age 18
years or older; an Eastern Cooperative Oncology Group performance status
between 0 and 1; an estimated life expectancy of 3 months or longer; and
adequate hematologic, renal, and liver functions. Patients were excluded if they
were pregnant or breastfeeding; had a history of brain metastasis, uncontrolled
hypertension, coronary disease or other significant cardiovascular disease,
gastrointestinal disorder, or other factors that could interfere with drug absorption;
were on anticoagulation therapy; had prior therapy with anti-VEGFR-targeting
agents; had a history of any other malignancy; or had recent prior chemotherapy,
radiotherapy, or surgery.
Twenty (10 men, 10 women) patients with a mean age of 55.2 years (range,
36–68 years) and a mean body mass index of 24.3 kg/m2 (range, 14.5–32.0 kg/m2)
participated in the study. These patients continuously received an oral dose of
750 mg of apatinib mesylate tablets (corresponding to 604 mg of apatinib free
base) once daily for 28 days. Blood samples (2–3 ml) for metabolism and
pharmacokinetic analyses were collected in heparinized tubes at 0 (predose),
0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours (before the next dose) on days 1 and 28,
as well as 48 hours after the last dosing. Samples were centrifuged at 1000g
for 10 minutes to separate the plasma fractions. The plasma samples were stored
at 220°C until analysis.
Metabolite Profiling and Identification
Sample Preparation. Representative pooled human plasma, urine, and fecal
homogenate samples were prepared for metabolite profiling. Equal volumes of
plasma samples collected from all cancer patients at 0 hour (predose) and 4 and
8 hours after the last dosing were pooled by time point. Excreta (urine and fecal
homogenates) samples from all healthy subjects were pooled in proportion to
the total sample weight over 24-hour intervals. For every 200-ml aliquot of
pooled plasma, urine, and fecal homogenate samples, 400 ml of acetonitrile was
added. After vortex-mixing and centrifugation at 11,000g for 5 minutes, the
supernatants were evaporated to dryness under a stream of nitrogen at 40°C.
The residues were then reconstituted in 100 ml of acetonitrile-water (1:9).
Reconstituted extract of pooled urine and fecal homogenate samples were
diluted at ratios of 1:4 and 1:40, respectively, with acetonitrile-water (1:9)
before analysis to achieve proper mass response. A 3-ml aliquot of the resulting
solution was injected for metabolite identification.
UPLC-UV/Q-TOF MS Analysis. The LC separation of the metabolites was
performed on an Acquity UPLC system (Waters Corporation, Milford, MA)
using an Acquity UPLC HSS T3 column (100 mm  2.1 mm, 1.8-mm particle
size; Waters Corporation). The column temperature was set to 40°C, and the
flow rate was kept to 450 ml/min. The mobile phase consisted of solvent A
(5 mM ammonium acetate solution with 0.05% formic acid) and solvent B
(acetonitrile), and a gradient method was used. The mobile phase was initially
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composed of solvent A/solvent B (95:5) and held for 2 minutes, then linearly
programmed to solvent A/solvent B (40:60) over 13 minutes, and held for 1
minute and to solvent B (100%) for 1 minute. The mobile-phase condition was
returned to the starting solvent mixture and allowed to equilibrate for 3 minutes
before the next injection. The effluent was monitored using a UV detector at
340 nm.
Mass spectrometry was performed using a Synapt Q-TOF high-resolution
mass spectrometer (Waters Corporation) operating in positive ion electrospray
mode. Nitrogen and argon were used as desolvation and collision gases,
respectively. The capillary and cone voltages were set to 3.5 kV and 50 V,
respectively. The desolvation gas was set to 700 l/h at a temperature of 350°C.
The source temperature was set to 100°C. The scan range was set at m/z (mass-
to-charge ratio) 8021000. All analyses were acquired using Lock Spray to
ensure accuracy and reproducibility. Leucine-enkephalin (m/z 556.2771) at
a concentration of 400 ng/ml and a flow rate of 3 ml/min was used for the lock
mass. Data were collected in centroid mode. Data acquisition was performed
using an alternating low and elevated collision energy (CE) scan mode, which
allowed for the simultaneous acquisition of molecular ion and fragmentation
ion data for all detected analytes within a single experiment. At low CE, the
transfer and trap CEs were 2 and 4 eV, respectively. At high CE, the transfer
CE was 15 eV and trap CE ramped from 5 to 25 eV.
Instrument control and postacquisition analyses were performed using
a MetaboLynx (v4.1) program (Waters Corporation), which uses mass defect
filtering and the dealkylation tool to generate a series of extracted ion
chromatograms (XICs). The XICs correspond to the ion currents that fall within
a 40-mDa window around the m/z values of the expected metabolites. The XICs
of the control and samples were compared to eliminate the chromatographic
peaks in the samples that also appear in the control (Zhang et al., 2008).
Fragmentations were proposed using the Mass Frontier 7.0 software (Thermo
Fisher Scientific Inc., San Jose, CA).
Enzyme Hydrolysis. Pooled human plasma and urine samples were adjusted
to pH 5 using citrate buffer and treated with 2000 units of b-glucuronidase. The
mixture was incubated in a water bath at 37°C for 16 hours; then the mixtures
were treated as described already and analyzed. Incubated plasma and urine
samples without the enzyme served as controls.
Reduction of N-Oxide Metabolites with Titanium Trichloride (TiCl3).
To identify N-oxides, the pooled human plasma and urine samples were treated
with TiCl3, which can selectively reduce N-oxides to their corresponding
amines (Kulanthaivel et al., 2004). TiCl3 solution (20 ml) was added to a
200-ml aliquot of plasma and urine. The mixtures were kept on ice for 2 hours
and neutralized with potassium hydroxide. Then the reaction mixtures were
treated as described previously herein and analyzed.
Synthesis of Apatinib-25-N-Oxide. A solution of apatinib mesylate (100 mg
in 1 ml of methanol) was added to a solution of m-chloroperbenzoic acid (100 mg
in 20 ml of dichloromethane) and stirred at room temperature for 24 hours
(Chelucci et al., 2008). The mixture was evaporated, and the residue was further
purified using a Shimadzu LC-6AD semipreparative HPLC apparatus equipped
with a SPD-20A UV detector. Separation was achieved using a YMC-Pack ODS-
A column (10  250 mm I.D., 5 mm; YMC Company Ltd., Kyoto, Japan). The
column oven was set to room temperature. Elution was performed using
methanol-water (70:30, v/v) at a flow rate of 3 ml/min. The detection wavelength
was set to 340 nm. The eluate at 9.8 minutes was collected and evaporated to
obtain the synthetic standard of M1-6 (70% yield).
Preparation of the Major Metabolites from Human Urine. Pooled bulk
urine samples were precipitated with methanol and concentrated to dryness.
The residue was dissolved in 50 ml of anhydrous methanol-water (1:9) and
Fig. 1. Mass spectrum of apatinib at high collision energy
(A) and the tentative structures of the most informative
fragment ions for apatinib (B). The structure of apatinib
could be divided into three parts (A, B, and C) based on the
fragmentation pattern.
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fractionated using YMC*GEL ODS-A-HG column chromatography (10%–
100% anhydrous methanol), yielding seven fractions (A–G). Fraction D eluted
by methanol-water (4:6) and fraction E eluted by methanol-water (5:5) were
further purified on a Shimadzu LC-6AD semipreparative HPLC apparatus
equipped with an SPD-20A UV detector. Chromatographic separation was
achieved using a YMC-Pack ODS-A column (10  250 mm internal diameter,
5 mm; YMC Company Ltd.). The mobile phase consisted of solvent A (water
with 0.1% formic acid) and solvent B (methanol), and a gradient method was
used. The detection wavelength was set to 340 nm. Fraction D afforded M8-2
(26 mg), and fraction E afforded M4-7 (3 mg), M6-9 (8 mg), M6-10 (15 mg),
and M9-2 (28 mg).
Quantification of Apatinib and Its Major Metabolites in Human Plasma
Apatinib, M1-1, M1-2, M1-6, and M9-2 were simultaneously determined
using a previously reported LC-MS/MS method (Ding et al., 2012). M9-1 was
also semiquantified using M9-2 as the calibration standard.
Pharmacokinetic Analysis
Standard noncompartmental methods were used to determine the pharma-
cokinetic parameters of apatinib and its metabolites using WinNonlin (Version
5.3; Pharsight, Mountain View, CA). The peak plasma concentration (Cmax)
and time to reach Cmax (Tmax) were taken directly from the pharmacokinetic
concentration-time data. The elimination rate constant (ke) value was estimated
using least-squares regression of the terminal log-linear phase of the concentration-
time curve, and the elimination half-life was calculated as ln2/ke. The area
under the plasma concentration-time curve (AUC0–24 hour) was calculated using
the linear-log trapezoidal method. The accumulation ratios (day 28/day 1) for
AUC0–24 hour and Cmax were also calculated.
Quantification of Apatinib and Its Major Metabolites in Human Urine and
Feces
The concentrations of apatinib and its metabolites M1-1, M1-2, M1-6, M4-7,
M6-9, M6-10, M8-2, and M9-2 in urine samples, as well as apatinib and its
metabolites M1-1, M1-2, M1-6, and M6-9 (for the semiquantification of total
dioxygenated metabolites) in fecal samples, were determined using the LC-MS/MS
method. This method was partially validated, including selectivity, linearity, in-
traday precision and accuracy, matrix effect, recovery, and stability.
The preparation procedures for the urine samples were similar to those for
the plasma except the resulting solution was diluted 10-fold with mobile
phase before analysis. To a 10-ml aliquot of fecal homogenous, 960 ml of
internal standard solution (500 ng/ml vatalanib) was added, and the mixture
was thoroughly vortex-mixed. A 20-ml aliquot of the resulting solution was
mixed with 180 ml of mobile phase before analysis. The LC-MS/MS analy-
tical conditions for urine and fecal sample analysis were similar to those for
plasma except more reaction monitoring transitions were selected: m/z
339–137 for M4-7, m/z 430 to (212 + 108) for M6-9 and M6-10, and m/z
499–323 for M8-2 were added for urine analysis; m/z 430–430 for M6-9 was
added for fecal sample analysis. For urine sample analysis, the method was
linear over the concentration range of 30.0–10,000 ng/ml for each analyte.
For fecal sample analysis, the method was linear over the concentration
ranges of 2.50–2000, 0.500–400, 0.250–200, 0.250–200, and 2.50–200 mg/g
Fig. 2. Metabolic profiles of apatinib after oral administration of 750 mg of apatinib mesylate to humans. (A) MDF (mass defect filter) metabolic profile of pooled plasma
samples collected 8 hours postdose at steady state; (B) UPLC-UV chromatogram of pooled plasma samples collected 8 hours postdose at steady state; (C) MDF metabolic
profile of 0- to 24-hour pooled urine samples; and (D) UPLC-UV chromatogram of pooled 0- to 24-hour urine samples; (E) MDF metabolic profile of 24- to 48-hour pooled
fecal samples; and (F) UPLC-UV chromatogram of pooled 24- to 48-hour fecal samples.
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for apatinib, M1-1, M1-2, M1-6, and M6-9, respectively. The amount of
apatinib and its major metabolites excreted in urine and feces during each
collection interval was calculated by multiplying the concentration of each
analyte by the volume or weight of the matrix collected over that interval. The
total urinary recovery or fecal recovery was calculated as the cumulative
amount excreted over all the collection periods and expressed as a percentage
of the administered dose.
Binding of Apatinib and Its Major Metabolites to Human Plasma Proteins
The binding of apatinib, M1-1, M1-2, and M1-6 to human plasma proteins
was measured by ultracentrifugation with similar methods as described
previously (Verbeke et al., 1979). Triplicate samples of apatinib, M1-1, M1-2,
and M1-6 at concentrations in the range of therapeutic plasma levels (500 ng/ml
for apatinib; 50 ng/ml for M1-1, M1-2, and M1-6) were tested, and data are
presented as mean 6 standard deviation.
In Vitro Pharmacological Activity of Major Metabolites
Metabolites M1-1, M1-2, M1-6, and M9-2 were screened for their activity
toward the inhibition of VEFGR-2, PDGFR-b, and c-kit RTKs using a
previously reported assay format (Hunt et al., 2004). For comparison, the
pharmacological activity of apatinib was also evaluated under the same
conditions. A pharmacological activity index (PAI) was calculated by dividing
the unbound concentration/in vitro potency ratio of each major metabolite by
the corresponding ratio of the parent drug to quantify the contribution of each
major metabolite to the overall effect of the drug (Leclercq et al., 2009). As
described previously, a PAI value greater than 25% means the metabolite may
Fig. 3. Proposed metabolic pathways of apatinib in humans.
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make a significant contribution to the effect of the drug activity (Smith and
Obach, 2005).
Oxidative Metabolism of Apatinib in Microsomes and Recombinant P450
and FMO Isoforms
Recombinant human CYP enzymes (CYP1A2, 1B1, 2A6, 2B6, 2C8, 2C9,
2C19, 2D6, 2E1, 3A4, 3A5, and 4A11) or FMO enzymes (FMO1, FMO2, and
FMO3) or microsomes (HLMs, HIMs, HPMs, and HRMs) were incubated
with apatinib. The incubation mixtures (200 ml) contained phosphate buffer
(100 mM, pH 7.4), P450 (50 pmol P450/ml) or FMO (0.25 mg protein/ml)
or microsomes (1 mg protein/ml), apatinib (2 mM), and NADPH (2 mM). After
1-hour incubation at 37°C, ice-cold acetonitrile (200 ml) was added to each
incubation to stop the reaction. Incubations were performed in duplicate and
analyzed by LC-MS/MS and UPLC-UV/Q-TOF MS.
HLM Incubations in the Presence of Selective P450 Inhibitors
The duration of incubation and the protein concentrations used above were
useful for initial experiments aimed at the identification of metabolites
in microsomal incubations, but they might not represent linear conditions.
To determine conditions that are linear for time of incubation and protein
concentration, 2 mM apatinib was incubated in HLMs (0–1.0 mg protein/ml) or
P450 enzymes (0–50 pmol P450/ml, CYP3A4, CYP3A5, or CYP2D6) with 2
mM NADPH at 37°C across a range of incubation times (0–90 minutes). Based
on the results obtained, a 10-minute incubation and a final HLM concentration
of 0.2 mg protein/ml and P450 enzyme concentration of 10 pmol P450/ml
represented conditions that are linear and were used in the subsequent
experiments.
The incubation mixtures (200 ml in duplicate) contained phosphate buffer
(100 mM, pH 7.4), HLM (0.2 mg protein/ml), apatinib (2 mM), NADPH
(1 mM), and a single selective P450 inhibitor. The chemical inhibitors used
were a-naphthoflavone (1 mM) for CYP1A1/2, sulfaphenazole (6 mM) for
CYP2C9, ticlopidine (10 mM) for CYP2B6 and CYP2C19, quinidine (2 mM)
for CYP2D6, ketoconazole (1 mM) for CYP3A4/5, chlormethiazole (24 mM)
for CYP2E1, and ABT (1 mM) for all the P450s. Metabolism-dependent
inhibitor ticlopidine was preincubated with HLM in the presence of NADPH
for 10 minutes before the substrate was added. After the substrate addition, the
samples were then incubated at 37°C for 10 minutes. Reactions were terminated
by the addition of an equal volume of ice-cold acetonitrile. The formations of
M1-1, M1-2, M1-3, M1-5, M1-6, M2, and M3-1 in the presence of inhibitors
were compared with metabolites formed in their absence.
To provide additional evidence for the contribution of FMOs to the
formation of M1-6 (pridine N-oxide), HLMs were heat-treated at 45°C for 5
minutes before incubation with apatinib. These treatment conditions would be
expected to inactivate the heat-sensitive FMOs but do not appreciably affect
P450 enzyme activities (Tugnait et al., 1997). Incubation conditions and sample
preparation were similar as described already herein.
Formation of M1-1, M1-2, and M1-6 by Recombinant P450 and FMO
Isoforms
To probe further the specific isoforms involved in the formation of major
oxidative metabolites (M1-1, M1-2, and M1-6), 2 mM apatinib was incubated
Fig. 4. Mean plasma concentration-time profiles of apatinib, M1-1, M1-2, M1-6, M9-1, and M9-2 after oral administration of 750 mg apatinib mesylate once daily for 28
day to 20 patients with advance colorectal cancer on days 1 (A) and 28 (B).
TABLE 3
Pharmacokinetic parameters (mean 6 S.D.) of apatinib and its major metabolites in human plasma after oral administration of 750 mg of apatinib mesylate once daily for 28
days to 20 patients with advanced colorectal cancer
Time Parameter Apatinib M1-1 M1-2 M1-6 M9-1 M9-2
Day 1 Tmax (h) 2.9 6 1.4 5.2 6 4.8 5.0 6 4.8 7.7 6 6.3 7.1 6 4.5 10.2 6 3.7
Cmax (nmol/l) 3819 6 2204 849 6 268 339 6 131 375 6 172 36.5 6 22.0 1543 6 819
AUC0–24 h (nmol·h/l) 30,941 6 18,794 12,458 6 4380 4796 6 2049 6605 6 2806 555 6 322 27,276 6 14,147
Day 28 Tmax (h) 4.7 6 2.2 7.2 6 6.2 7.0 6 6.1 5.5 6 2.4 11.5 6 8.0 11.3 6 6.9
Cmax (nmol/l) 3935 6 2211 1470 6 418 571 6 162 786 6 210 94.3 6 55.5 2843 6 1226
AUC0–24 h (nmol·h/l) 46,285 6 17,883 26,014 6 8895 10,001 6 4107 14,596 6 4090 2168 6 1184 57,631 6 24,888
t1/2 (h) 18.6 6 9.2 24.7 6 12.9 23.2 6 12.3 21.2 6 12.7 26.3 6 15.9 23.8 6 9.7
Day 28/day 1 Cmax ratio 1.16 6 0.82 1.78 6 0.79 1.76 6 0.97 2.41 6 1.75 3.01 6 2.15 1.84 6 1.13
AUC0–24 h ratio 1.77 6 1.17 2.18 6 1.13 2.20 6 1.38 2.51 6 1.79 3.69 6 2.95 2.17 6 1.35
AUC, area under the curve; Cmax, peak plasma concentration; t1/2, elimination half-life; Tmax, time to reach Cmax.
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with recombinant human CYP1A2, 1B1, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6,
2E1, 3A4, 3A5, and 4A11 (10 pmol P450/ml) or FMO1, FMO2, and FMO3
(0.2 mg protein/ml) at 37°C for 10 minutes (final incubation volume 200 ml).
The incubations were initiated by the addition of 1 mM NADPH and terminated
by the addition of 200 ml of ice-cold acetonitrile. Incubations were conducted
in duplicate and analyzed by LC-MS/MS.
In Vitro Enzyme Kinetic Study
Enzyme kinetic parameters for the formation of M1-1, M1-2, and M1-6 were
evaluated in HLMs (0.2 mg of protein/ml) and recombinant CYP3A4,
CYP3A5, and CYP2D6 enzymes (10 pmol P450/ml). Incubations were
performed at 37°C for 10 minutes. The substrate concentration ranged from 0.1
to 15 mM. Data are presented as averages of triplicate experiments. Kinetic
constants were obtained by fitting Michaelis-Menten equation (V = Vmax  S/
(Km + S)) to experimental data using nonlinear regression (Prism 5.0; GraphPad
Software Inc., San Diego, CA). V is the reaction velocity, Vmax is the maximum
velocity, Km is the Michaelis constant (substrate concentration at 0.5 Vmax), and
S is the substrate concentration. In vitro intrinsic clearance (CLint) was
calculated as Vmax/Km. The fitness of the model was investigated based on
visual inspection of the Eadie-Hofstee plots (corresponding to V against V/S)
and calculated correlation coefficient.
Phase 2 Microsomal Incubations
The protein content and time linearity were proven in the preceding analysis.
M1-1 and M1-2 (20 mM) were incubated with HLMs, HIMs, HPMs, and
HRMs (0.5 mg protein/ml in 100 mM Tris-HCl buffer containing 8 mM MgCl2
and 25 mg/ml alamethicin, pH 7.5) at 37°C for 1 hour with or without 2 mM
UDPGA in a total volume of 200 ml. After preincubation of the reaction
mixtures for 5 minutes at 37°C, the reactions were initiated by the addition of
UDPGA and terminated by the addition of 200 ml ice-cold acetonitrile.
Incubations were performed in duplicate and analyzed by UPLC-UV/Q-TOF
MS.
O-Glucuronidation of M1-1 and M1-2 by Recombinant UGT Isoforms
The enzymes involved in the O-glucuronidation of M1-1 and M1-2 were
determined using a panel of recombinant human UGT enzymes, including
UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9,
UGT1A10, UGT2B4, UGT2B7, UGT2B15, and UGT2B17. The concentration
TABLE 4
Excretion of total drug-related compounds in urine and feces after a single oral administration of 750 mg of apatinib mesylate tablets to 12 healthy subjects
Time
Period (h)
%Dose Recovered by Subject
Male Female Mean 6 S.D.
1 2 3 4 5 6 1 2 3 4 5 6 Total Male Female
Urine
0–4 0.924 0.453 0.757 0.560 0.780 0.333 0.483 0.460 0.484 0.545 0.528 0.364 0.556 6 0.177 0.635 6 0.223 0.477 6 0.064
0–8 2.42 1.04 2.02 1.60 1.90 0.705 0.873 1.51 1.33 2.10 1.25 1.45 1.52 6 0.52 1.61 6 0.64 1.42 6 0.40
0–12 3.48 1.46 3.36 2.00 2.76 0.951 1.47 2.25 2.02 3.88 1.77 2.41 2.32 6 0.90 2.33 6 1.03 2.30 6 0.85
0–24 5.56 2.58 5.07 3.04 4.84 1.68 3.56 4.36 3.30 6.60 2.65 4.28 3.96 6 1.42 3.80 6 1.57 4.13 6 1.37
0–36 7.42 3.74 6.85 3.80 6.19 2.58 4.96 5.79 4.43 8.50 3.38 5.54 5.26 6 1.78 5.10 6 1.97 5.43 6 1.73
0-48 8.12 4.22 7.77 4.37 6.90 3.29 5.80 6.75 5.34 9.28 3.98 6.02 5.99 6 1.85 5.78 6 2.06 6.20 6 1.77
0–72 8.90 4.49 8.19 4.80 7.59 5.22 6.77 7.41 6.25 10.1 4.73 6.76 6.77 6 1.78 6.53 6 1.92 7.01 6 1.78
0–96 9.06 4.63 8.25 4.86 7.76 5.67 7.46 7.63 6.56 10.4 4.98 7.04 7.02 6 1.77 6.70 6 1.89 7.34 6 1.76
Feces
0–24 5.10 35.1 30.9 NA NA NA NA NA NA NA 42.5 0.623 9.52 6 16.3 11.9 6 16.6 7.19 6 17.3
0–48 5.10 81.3 55.2 82.0 24.4 NA 51.9 63.2 79.3 0.008 68.4 59.5 47.5 6 31.8 41.3 6 36.7 53.7 6 27.9
0-72 66.6 81.3 55.2 94.7 54.0 NA 55.6 67.1 85.2 44.0 68.4 65.4 61.5 6 24.1 58.6 6 32.7 64.3 6 13.8
0–96 72.5 95.3 55.9 96.6 58.5 55.3 62.0 68.7 87.6 46.3 71.0 67.9 69.8 6 16.1 72.4 6 19.3 67.3 6 13.4
Urine + feces
0–24 10.7 37.7 36.0 3.04 4.84 1.68 3.56 4.36 3.30 6.60 45.1 4.91 13.5 6 16.0 15.6 6 16.7 11.3 6 16.6
0-48 13.2 85.5 63.0 86.4 31.3 3.29 57.7 70.0 84.6 9.29 72.4 65.5 53.5 6 31.0 47.1 6 36.3 59.9 6 26.3
0-72 75.5 85.8 63.4 99.5 61.6 5.22 62.4 74.5 91.5 54.1 73.1 72.2 68.2 6 23.8 65.2 6 32.6 71.3 6 12.6
0–96 81.6 99.9 64.2 101.5 66.3 61.0 69.5 76.3 94.2 56.7 76.0 74.9 76.8 6 14.9 79.1 6 18.2 74.6 6 12.1
NA, not applicable.
Fig. 5. Mean cumulative urine excretion (A) and fecal excretion (B) of apatinib and its major metabolites after a single oral administration of 750 mg of apatinib mesylate to
12 healthy Chinese volunteers.
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of the UGT enzymes was 0.5 mg of protein/ml. Incubations were performed in
duplicate and analyzed by LC-MS/MS.
Inhibition of O-Glucuronidation of M1-1 and M1-2 by Selective UGT
Inhibitors
Mefenamic acid (Mano et al., 2007a) and flurbiprofen (Mano et al., 2007b),
two potent inhibitors of UGT2B7, as well as hecogenin (Uchaipichat et al.,
2006), a potent inhibitor of UGT1A4, were tested for their inhibitory effect on
the O-glucuronidation of M1-1 and M1-2 in HLMs. To determine the IC50
values of these inhibitors, M1-1 and M1-2 (20 mM) were incubated in the
absence and presence of mefenamic acid (0.2–20 mM), racemic flurbiprofen
(1–200 mM), or hecogenin (1–100 mM) in HLMs. Incubations were performed
in duplicate and analyzed by LC-MS/MS.
Results
Metabolite Profiling and Identification.Metabolites of apatinib in
human plasma, urine, and fecal samples were identified based on
the generated elemental composition of ions obtained from accurate
mass measurements, specific MS fragmentation pattern, and cochro-
matography (when standard available). The chromatographic and MS
fragmentation behaviors of apatinib were first investigated to aid in the
structural assignment of the metabolites. Apatinib had a retention time
of 11.4 minutes on the HPLC system and showed a protonated
molecule ion at m/z 398.189. The high CE mass spectrum (Fig. 1A)
showed a major fragment ion at m/z 212.082, which was formed
through cleavage of the nicotinamide amide bond and charge retention
on the pyridyl moiety. The fragment ion at m/z 371.190 was formed
through the cleavage of the cyano group. The fragment ion at m/z
184.087 represented the picolyl-aminopyridine moiety. The fragment
ion at m/z 92.049 represented the picolyl group. Based on the MS
fragment pattern, the structure of apatinib was divided into parts A, B,
and C (Fig. 1B). The structures of the metabolites were then tentatively
characterized by determining the changes in the m/z values of these
three segments. The proposed MS fragmentation pattern of apatinib is
shown in Fig. 1B.
After being processed using the mass defect filtering and dealkylation
techniques, a total of 23, 35, and 14 metabolites of apatinib were
detected in human plasma, urine, and feces, respectively (Fig. 2, A,
C, and E). The corresponding UV chromatograms are shown in
Fig. 2, B, D, and F, respectively. Based on the UV chromatograms,
M9-2 was the major circulating drug-related component at steady
state, followed by M0, M1-1, M1-6, and M1-2. The major components
in urine included M1-1, M1-2, M6-9, M6-10, M8-2, and M9-2. M0
was the predominant component in feces, followed by M1-1, M6-7,
M6-5, and M1-2. Table 1 lists the detailed information of the
possible metabolites of apatinib, including protonated molecule ion,
proposed elemental composition, retention time of each chromato-
graphic peak, relative MS peak area, and the characteristic fragment
ions. The proposed metabolic pathways of apatinib in humans are
shown in Fig. 3. A description of the information used for the
assignment of each metabolite is detailed in Supplemental Results.
Nine major metabolites (M1-1, M1-2, M1-6, M4-7, M4-8, M6-9,
M6-10, M8-2, and M9-2) were confirmed by comparison with reference
standards. The 1H NMR data of reference standards are listed in
Table 2.
Pharmacokinetic Evaluation in Patients with Advanced Co-
lorectal Cancer. The plasma concentration-time profiles of apatinib
and its metabolites M1-1, M1-2, M1-6, M9-1, and M9-2 after oral
administration of 750 mg of apatinib mesylate once daily for 28 day to
patients with advanced colorectal cancer are shown in Fig. 4. A
summary of their main pharmacokinetic parameters is presented in
Table 3.
After the first dose, the Cmax of apatinib, M1-1, M1-2, M1-6, M9-1,
and M9-2 were achieved approximately 2.9 to 10.2 hour postdose,
with mean values of 3819, 849, 339, 375, 36.5, and 1543 nmol/l,
respectively. During the first 24 hours after dosing, the systemic exposures
TABLE 5
Binding of apatinb, M1-1, M1-2, and M1-6 to human plasma proteins and the in vitro pharmacological study results of
M1-1, M1-2, M1-6, and M9-2
Group Analyte Percent Protein Bindinga
IC50 (nM) PAI (%)
b
VEGFR-2 PDGFR-b c-kit VEGFR-2 PDGFR-b c-kit
1 Apatinib 92.4 6 3.2 1.90 16.5 12.9 100 100 100
M1-1 90.1 6 2.2 19.2 46.9 125 5.42 19.3 5.66
M1-2 88.0 6 3.2 179 1352 2511 0.22 0.25 0.11
2 Apatinib 92.4 6 3.2 3.30 11.4 29.3 100 100 100
M1-6 75.8 6 3.7 265 369 981 0.32 0.80 0.77
M9-2 Not measured Inactive Inactive Inactive Inactive Inactive Inactive
AUC, area under the curve; PAI, pharmacological activity index; PDGFR-b, platelet-derived growth factor receptor-b; VEGFR-2,
vascular endothelial growth factor receptor-2.
a Percent protein binding was measure by ultracentrifugation.
b PAI was calculated as follows: PAI = (metabolite AUC at steady state  percent protein binding of metabolite  IC50 of parent)/
(parent AUC at steady state  parent percent protein binding  IC50 of metabolite)  100.
Fig. 6. Incubation of apatinib (2 mM) in recombinant human P450 and FMO
enzymes and HLMs in the presence of 2 mM NADPH at 37°C for 1 hour. Each bar
represents the mean of duplicate determinations.
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of M1-1, M1-2, M1-6, M9-1, and M9-2 (based on molar concen-
trations) were approximately 40, 16, 21, 2, and 88% that of the parent
drug, respectively.
After the last dose, the Cmax values of apatinib, M1-1, M1-2, M1-6,
M9-1, and M9-2 were achieved approximately 4.7 to 11.5 hours
postdose, with mean values of 3935, 1470, 571, 786, 94.3, and 2843
nmol/l, respectively. During the first 24 hours after dosing, the
systemic exposures of M1-1, M1-2, M1-6, M9-1, and M9-2 (based on
molar concentrations) were approximately 56, 22, 32, 5, and 125%
that of the parent drug, respectively. Therefore, M9-2 was the major
circulating drug-related component at steady state, followed by
parent drug, M1-1, M1-6, M1-2, and M9-1. The elimination half-life
of apatinib, M1-1, M1-2, M1-6, M9-1, and M9-2 averaged 18.6,
24.7, 23.2, 21.2, 26.3, and 23.8 hours, respectively, indicating that
systemic clearance for metabolites was slightly slower than that for
the parent compound. After repeated administration, the AUC0–24 hour
accumulation ratios of apatinib and its metabolites were 1.77–
3.69. The Cmax accumulation ratios of apatinib and its metabolites
Fig. 7. Effect of P450 selective chemical inhibitors on the formation of major metabolites in HLMs. A 10-minute incubation and a final HLM concentration of 0.2 mg of
protein/ml represented conditions that are linear and were used in this experiments. Each column represents the mean percentage activity relative to vehicle control from
duplicate measurements.
Fig. 8. Formation of M1-1, M1-2, and M1-6 from apatinib (2 mM)
incubation in individual human recombinant P450 enzyme. Each bar
represents the mean activity from duplicate measurements.
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were 1.16 to 3.01, respectively. Gender difference in the pharma-
cokinetics of apatinib in humans was not observed (unpublished
data).
Excretion of Apatinib in Humans. The cumulative recovery of
total drug-related compounds in urine, feces, and the sum of urine and
feces after a single oral administration of 750 mg of apatinib mesylate
to 12 healthy subjects is shown in Table 4. The total drug-related
compounds were excreted predominantly in feces (69.8% 6 16.1% of
dose), and only a minor proportion was excreted renally (7.02% 6
1.77% of dose). The average cumulative excretion was 76.8% 6
14.9%. As shown in Fig. 5, 59.0% of the administered dose was
excreted as unchanged drug in feces. The metabolites M1-1, M1-2,
M1-6, and total dioxygenated metabolites excreted in feces ac-
counted for 2.76, 1.20, 0.02, and 6.80% of the administered dose,
respectively. Unchanged apatinib was detected only in negligible
quantities in urine. The metabolites M1-1, M1-2, M1-6, M4-7, M6-9,
M6-10, M8-2, and M9-2 excreted in urine accounted for 0.567,
0.386, 0.982, 0.101, 0.472, 1.10, 1.87, and 1.53% of the dose,
respectively. Gender difference in the excretion of apatinib was not
observed.
Binding of Apatinib and Its Major Metabolites to Human
Plasma Proteins. The percentage protein binding of apatinib, M1-1,
M1-2, and M1-6 at concentrations in the range of therapeutic plasma
levels are listed in Table 5.
Fig. 9. Kinetic analysis for the formation of M1-1, M1-2, and M1-6 in HLMs (A), as well as human recombinant CYP3A4 (B), CYP3A5 (C), and CYP2D6 (D). Apatinib
was incubated at concentrations in the range of 0.1–15 mM in triplicate.
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In Vitro Pharmacological Activity of Major Metabolites. In vitro
pharmacological study results of major metabolites are listed in
Table 5. M1-1 potently inhibited VEGFR-2, PDGFR-b, and c-kit with
IC50 of 19, 47, and 125 nM, respectively. M1-2 moderately inhibited
VEFGR-2, PDGFR-b, and c-kit with an IC50 of 179, 1352, and 2511
nM, respectively. M1-6 moderately inhibited VEFGR-2, PDGFR-b,
and c-kit with IC50 of 265, 369, and 981 nM, respectively. M9-2 did
not inhibit the kinase activity of either enzyme to any significant
extent. The PAI values of M1-1 toward VEFGR-2, PDGFR-b, and
c-kit were 5.42, 19.3, and 5.66% compared with parent drug, re-
spectively. The PAI values of M1-2 and M1-6 toward VEFGR-2,
PDGFR-b, and c-kit were all less than 1% compared with the parent
drug.
Oxidative Metabolism of Apatinib in Microsomal and Cyto-
chrome Enzyme Incubations. As shown in Fig. 6, after 1-hour
microsomal or cytochrome enzyme incubations, approximately 50%
of the parent compound was consumed in the HLM incubations,
whereas only 13% was used in the HIM incubations. Apatinib was not
metabolized by HRMs and HPMs. Therefore, the liver was suspected
to be the major oxidative biotransformation site for apatinib. More
than 95% of the parent compound was consumed in CYP2D6,
CYP3A4, and CYP3A5 incubations. About 30 to 50% of the parent
compound was consumed in CYP2C9 and CYP2E1 incubations, and
about 5 to 15% of the parent compound was consumed in CYP1B1,
CYP2C8, and CYP2C19 incubations. Less than 5% of the parent
compound was consumed in CYP1A2, CYP2A6, CYP2B6, CYP4A11,
FMO1, FMO3, and FMO5 incubations, indicating that these cyto-
chrome and FMO enzymes contributed minimally to the metabolism of
apatinib.
In an NADPH-dependent manner, apatinib was metabolized by
HLMs into seven metabolites: M1-1, M1-2, M1-3, M1-5, M1-6, M2,
and M3-1. M1-2 was the main in vitro metabolite based on the peak
areas obtained. The absence of NADPH in the incubations implies the
absence of any metabolites.
HLM Incubations in the Presence of Selective P450 Inhibitors.
The inhibition results generated from selective chemical inhibitors on
the formation of M1-1, M1-2, M1-3, M1-5, M1-6, M2, and M3-1 in
HLM incubations are shown in Fig. 7. Compared with the control sam-
ples without inhibitors, incubation with a-naphthoflavone (CYP1A1/2
inhibitor) and chlormethiazole (CYP2E1 inhibitor) had no substantial
effect on the formation of all the metabolites. Sulphaphenazole
(CYP2C9 inhibitor) inhibited the formation of M1-1, M1-2, M1-3, M1-6,
TABLE 6
Kinetic parameters (mean 6 S.D.) for the formation of M1-1, M1-2, and M1-6 in HLMs as well as in human
recombinant CYP3A4, CYP3A5, and CYP2D6
Metabolite Kinetic Parameters HLM CYP3A4 CYP3A5 CYP2D6
M1-1 Km (mM) 1.93 6 0.33 0.57 6 0.13 0.28 6 0.05 0.69 6 0.15
Vmax
a 3.28 6 0.19 0.05 6 0.003 0.02 6 0.0007 1.07 6 0.06
CLint
b 1.70 6 0.21 0.09 6 0.02 0.07 6 0.01 1.56 6 0.29
R2 0.9726 0.9125 0.9318 0.9455
M1-2 Km (mM) 2.18 6 0.29 0.90 6 0.15 0.26 6 0.03 NA
Vmax 39.1 6 1.79 1.29 6 0.06 0.88 6 0.02 NA
CLint 17.9 6 1.74 1.44 6 0.20 3.38 6 0.35 NA
R2 0.9849 0.9644 0.9753 NA
M1-6 Km (mM) 1.41 6 0.22 1.02 6 0.17 0.30 6 0.03 0.53 6 0.12
Vmax 9.82 6 0.46 0.31 6 0.01 0.16 6 0.004 4.60 6 0.24
CLint 7.01 6 0.83 0.30 6 0.04 0.52 6 0.05 8.68 6 1.61
R2 0.9765 0.9687 0.9792 0.9388
CLint, intrinsic clearance; HLM, human liver microsome; Km, Michaelis constant; NA, not applicable; R
2, calculated correlation
coefficient.
aThe unit for Vmax was pmol/min/mg protein for HLM and pmol/min/pmol P450 for CYP3A4, CYP3A5, and CYP2D6.
bThe unit for CLint was ml/min/mg protein for HLM and ml/min/pmol P450 for CYP3A4, CYP3A5, and CYP2D6.
Fig. 10. O-Glucuronidation of M1-1 to form M9-2 (j) and M1-2 to
form M9-1 (u) at substrate concentration of 20 mM by 12 human
recombinant UGTs. Each column represents the mean of duplicate
determinations.
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and M2 by 18% to 39% and did not inhibit the formation of M1-5 and
M3-1. Ticlopidine (inhibitor of CYP2B6 and CYP2C19) inhibited the
formation of M1-2 and M1-3 by 17 and 29%, respectively, and did
not inhibit the formation of other metabolites. Quinidine (CYP2D6
inhibitor) inhibited the formation of M1-1, M1-2, M1-3, and M1-6 by
18 to 36% and did not inhibit the formation of M1-5, M2, and M3-1.
Ketoconazole (CYP3A4/5 inhibitor) inhibited the formation of M1-1,
M1-2, M1-3, M1-6, M2, and M3 by 44, 82, 91, 66, 75, and 96%,
respectively, but did not inhibit the formation of M1-5. ABT (inhibitor
of all the cytochrome enzymes) inhibited the formation of M1-1, M1-
2, M1-3, M1-5, M1-6, M2, and M3 by 78, 95, 100, 46, 97, 82, and
100%, respectively, suggesting the involvement of P450s in all
metabolites yield. Heat treatment of HLM did not affect M1-6
(pridine-N-oxide) formation, thus excluding involvement of FMOs in
M1-6 formation.
Formation of Major Oxidative Metabolites by Recombinant
P450 Isoforms. As shown in Fig. 8, FMOs were not capable of
apatinib metabolism. All tested cytochrome isoforms were capable of
M1-1 and M1-2 formation. M1-1 was produced to the greatest extent
by CYP2D6 (0.226 pmol/min/pmol protein) and to a lesser extent by
CYP3A4 (0.037 pmol/min/pmol protein) and CYP3A5 (0.014 pmol/
min/pmol protein). Other cytochromes also catalyzed the production
of M1-1 but to much less extent. M1-2 was produced to the greatest
extent by CYP3A4 (0.748 pmol/min/pmol protein) and CYP3A5
(0.710 pmol/min/pmol protein). M1-6 was predominantly formed by
CYP2D6 (1.28 pmol/min/pmol protein) and to a lesser extent by
CYP3A4 (0.210 pmol/min/pmol protein) and CYP3A5 (0.148 pmol/
min/pmol protein).
In Vitro Enzyme Kinetic Study. The formation of M1-1, M1-2,
and M1-6 by HLMs, CYP3A4, CYP3A5, and CYP2D6 exhibited
Michaelis-Menten kinetics (Fig. 9). Table 6 presents the enzyme
kinetic variables for the formation of M1-1, M1-2, and M1-6 in
HLMs, CYP3A4, CYP3A5, and CYP2D6. Vmax and Km values for the
formation of M1-1, M1-2, and M1-6 in CYP3A4 were all higher than
that observed in CYP3A5, resulting in the comparable in vitro intrinsic
clearance (Vmax/Km) in CYP3A4 and CYP3A5. The high Vmax and
CLint values for the formation of M1-1 and M1-6 in CYP2D6 suggest
that CYP2D6 has a high capability for the formation of M1-1 and
M1-6. Enzyme kinetics of M1-2 formation in CYP2D6 was not
determined because CYP2D6 catalyzed the formation of negligible
M1-2.
Microsomal Conjugation of M1-1 and M1-2. M9-2 and M9-1 are
E- and Z-isomers. M9-2 was the major circulating drug-related com-
ponent at steady state, whereas M9-1 was present only in negligible
quantities in human plasma. To investigate the selectivity, M1-1 and M1-2
were individually incubated with HLMs, HIMs, HPMs, and HRMs.
O-glucuronidation of M1-1 to form M9-2 in the HLMs and HRMs
was similar, whereas negligible amounts of M9-2 were formed in
HIMs and HPMs (unpublished data). The highest M9-1 formation was
observed in HLMs. The formation of M9-1 in HRMs was approximately
50% that in HLMs. Negligible amounts of M9-1 were formed in HIMs
and HPMs (unpublished data). In HLMs, the formation of M9-2 was 8
times higher than that of M9-1. In HRMs, the formation of M9-2 was 16
times higher than that of M9-1.
UGT Enzymes Responsible for the Glucuronidation of M1-1
and M1-2. M1-1 and M1-2 were incubated with 12 individual UGT
isoforms to identify the UGT enzymes responsible for the formation of
M9-2 and M9-1 (Fig. 10). UGT1A1, UGT1A3, UGT1A4, UGT1A8,
UGT1A9, UGT2B4, UGT2B7, and UGT2B17 all catalyzed the
formation of M9-2, with UGT2B7 having the highest activity.
UGT1A1, UGT1A3, UGT1A4, UGT1A8, UGT2B4, and UGT2B7
all catalyzed the formation of M9-1, with UGT1A4 having the highest
activity, followed by UGT2B7. UGT2B7 is abundantly expressed in
the liver, small intestine, colon, and kidney, whereas UGT1A4 is
expressed only at relatively low levels in the liver (Ohno and Nakajin,
2009). Thus, both UGT1A4 and UGT2B7 may play important roles in
the formation of M9-1.
The inhibitory effect of mefenamic acid (UGT2B7 inhibitor),
racemic flubiprofen (UGT2B7 inhibitor), and hecogenin (UGT1A4
inhibitor) on the formation of M9-2 and M9-1 in HLMs was evaluated.
As shown in Fig. 11, mefenamic acid inhibited M9-2 and M9-1
formation in HLMs with an IC50 of 2.64 mM (2.17–3.23 mM) and
8.35 mM (6.74–10.7 mM), respectively. Racemic flubiprofen inhib-
ited M9-2 and M9-1 formation in HLMs with an IC50 of 13.6 mM
(10.6–17.0 mM) and 44.4 mM (36.8–54.2 mM), respectively.
Hecogenin showed little inhibitory effect on M9-2 formation. The
IC50 of hecogenin was 45.7 mM (24.1–138 mM) for M9-1 formation.
These results strongly suggest that UGT2B7 was the main enzyme
Fig. 11. Inhibitory effects of mefenamic acid, flurbiprofen, and hecogenin on the O-glucuronidation of M1-1 to form M9-2 (A) and M1-2 to form M9-1 (B) at a substrate
concentration of 20 mM in HLMs. Data represent the mean of duplicate determinations.
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responsible for M9-2 formation and that both UGT1A4 and UGT2B7
were responsible for M9-1 formation.
Discussion
The studies summarized in this article focus on the metabolism,
pharmacokinetics, and excretion of apatinib after oral administra-
tion of 750 mg of apatinib mesylate to humans. Plasma samples
for metabolism and pharmacokinetic analysis were collected from
patients with advanced colorectal cancer. Urine and fecal samples
for metabolism and excretion studies were collected from healthy
subjects.
A total of 23, 35, and 14 metabolites were detected in human plasma,
urine, and feces, respectively, by UPLC/Q-TOF MS. The proposed
structures of the nine major metabolites M1-1, M1-2, M1-6, M4-7,
M4-8, M6-9, M6-10, M8-2, and M9-2 were confirmed by compa-
rison with reference standards after HPLC cochromatography, mass
spectrometry, and NMR. The metabolic scheme of apatinib in humans
is shown in Fig. 3. Systemically available apatinib was extensively
metabolized in humans. The primary routes of apatinib biotransfor-
mation involved E- and Z-cyclopentyl-3-hydroxylation, N-dealkylation,
pyridyl-25-N-oxidation, 16-hydroxylation, dioxygenation, and O-
glucuronidation after cyclopentyl-3-hydroxylation. Apatinib shared
some common metabolic pathways with its analog motesanib
(Li et al., 2009), such as pyridyl-N-oxidation and N-dealkylation.
However, the major metabolic reactions of apatinib occurred on
the cyclopentyl group, including hydroxylation and further O-
glucuronidation.
Total recovery of drug-related compounds accounted for 76.8% of
the dose. Most of the recovered dose was eliminated via feces (69.8%
of the dose). Only a minor proportion was excreted through urine
(7.02% of the dose). About 59.0% of the total intake dose of apatinib
was excreted unchanged within 0–96 hours via feces. The substantial
fecal recovery of apatinib may be related to 1) nonabsorbed drug; 2)
biliary excretion of apatinib; 3) unstable metabolites that convert back
apatinib by intestinal bacterial enzymes after biliary transport into the
intestine, such as the N-oxide (el-Mekkawy et al., 1993); or 4) direct
intestinal excretion after absorption. Apatinib exhibited poor oral
bioavailability after a single oral administration of apatinib mesylate to
dogs (9.24% in male dogs, 15.4% in female dogs, unpublished data).
Thus, the apatinib recovered in feces was suspected to represent mainly
the nonabsorbed drug. In addition, the pyridyl-25-N-oxide metabolite
(M1-6), which was found in plasma and urine, was detected only in
negligible quantities in feces. These observations were in agreement
with the reductive potential of human intestinal bacteria toward N-
oxides. The excretion of M1-1, M1-2, M1-6, and total dioxygenated
metabolites in feces accounted for 2.76, 1.20, 0.02, and 6.80% of the
administered dose, respectively. Unchanged apatinib was detected only in
negligible quantities in urine, indicating that the systemically available
apatinib was extensively metabolized. The major metabolites M1-1, M1-2,
M1-6, M4-7, M6-9, M6-10, M8-2, and M9-2 excreted in urine each
accounted for less than 2% of the dose. Gender difference in the excretion
of apatinib was not observed.
The major circulating metabolites may contribute to the overall
efficacy and toxicity of the drug. Thus, determination of the phar-
macokinetics of the major metabolites of a new drug is essential. The
pharmacokinetics of unchanged apatinib in this study was comparable
to data previously reported in cancer patients (Li et al., 2010). Cmax
of apatinib was achieved 2.9 to 4.7 hour postdose. Significant
interpatient variability with apatinib indicated that dose modifica-
tion may be needed to meet individual needs. The major circulating
metabolite was the pharmacologically inactive metabolite M9-2, the
steady-state exposure of which was 125% that of the parent drug at
steady state. The systemic exposures of M1-1, M1-2, and M1-6 were
56, 22, and 32% that of the parent drug, respectively. Calculated as PAI
values, the contribution of M1-1 to the pharmacology of the drug was
5.42 to 19.3% that of the parent drug, and the contribution of M1-2 and
M1-6 to the pharmacology of the drug was less than 1% that of the
parent drug. Therefore, among the prominent systemically available
drug-related components, the parent drug was considered to have major
contributions to the overall pharmacological activity in humans; active
mono-oxygenated metabolites M1-1, M1-2, and M1-6 were considered
to have only minor contributions. The systemic clearance for all the
metabolites quantified was slightly slower than that for the parent drug.
The accumulation degrees of apatinib and its metabolites were observed
to be moderate, with mean AUC0–24 hour accumulation ratios ranging
from 1.77 to 3.69.
The oxidative metabolites of apatinib were formed mainly in the
liver in an NADPH-dependent manner. In vitro metabolism studies
with recombinant human isozymes and inhibition studies with
selective chemical inhibitors of human P450 enzymes demonstrated
that the oxidative metabolism of apatinib was mediated by CYP3A4/5
and, to a lesser extent, by CYP2D6, CYP2C9, and CYP2E1. All tested
cytochrome isoforms were capable of M1-1 and M1-2 formation.
M1-1 was produced to the greatest extent by CYP2D6 and to a lesser
extent by CYP3A4 and CYP3A5. M1-2 was produced to the greatest
extent by CYP3A4 and CYP3A5. M1-6 was predominantly formed
by CYP2D6 and to a lesser extent by CYP3A4 and CYP3A5. N-
dealkylation of apatinib was mediated predominantly by CYP3A4/5.
Hydroxylation and dealkylation are most common metabolic path-
ways observed in CYP2D6 substrates, whereas N-oxidation is far less
common in CYP2D6 substrate. However, there are a few prior
examples of CYP2D6-mediated formation of N-oxide. Procainamide
(Lessard et al., 1999), sparteine (Zhou et al., 2009), citalopram (Olesen
et al., 1999), AZD0328 {(29R)-spiro[1-azabicyclo[2.2.2]octane-3,29(39H)-
furo[2,3-b]pyridine]} (Zhou et al., 2011), and another AZD0328
structure similar a7 NNR agonist {N-(3R)-1-azabicyclo[2.2.2]oct-
3-ylfuro[2,3-c]pyridine-5-carboxamide} (Shaffer et al., 2007) probably
are the only limited number of compounds reported previously to have
N-oxidation catalyzed by CYP2D6.
The kinetic analysis indicated higher Vmax but lower binding
affinity for the formation of M1-1, M1-2, and M1-6 in CYP3A4 than
that observed in CYP3A5, indicating the comparable in vitro intrinsic
clearance (Vmax/Km) in CYP3A4 and CYP3A5. Although CYP2D6
has a higher capability for the formation of M1-1 and M1-6 than
CYP3A4 and CYP3A5, results of the in vitro inhibition studies with
selective chemical inhibitors indicated that CYP2D6 are not expected
to play a significant role in the hepatic clearance of apatinib in
humans.
The concomitance of known CYP3A4/5 inducers, inhibitors, or
substrate may influence drug levels of apatinib. Further in vivo studies
will be conducted to evaluate the clinical drug-drug interaction.
Hypertension is observed as an adverse effect of all the oral VEGF
tyrosine kinase inhibitors (Izzedine et al., 2007), which have occurred
because the inhibition of VEGFR in arterial endothelial cells decreases
the release of nitric oxide (Tang et al., 2004). In phase 1 clinical
studies of apatinib, 68% of the patients who took the drug experienced
hypertension. Many antihypertensive drugs, such as amlodipine,
diltiazem, felodipine, nicardipine, nifedipine, and verapamil, were the
substrates or inhibitors of CYP3A. Thus, the concomitant use of these
antihypertensive medications with apatinib in patients may induce
drug-drug interactions. The potential for drug interactions with M1-1
and M1-6 (metabolite present at greater than 25% of parent drug
AUC) should be considered in the following studies according to Food
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and Drug Administration guidance (http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.
pdf).
M9-2 (O-glucuronide of M1-1) and M9-1 (O-glucuronide of M1-2)
were E- and Z-isomers. Measured as AUC0–24 hour ratios at steady
state, the plasma exposure of M1-1 was 1.6-fold higher than that of
M1-2, whereas the plasma exposure of M9-2 was 25.6-fold higher
than that of M9-1. These observations suggested that the formation of
M9-2 is preferred over M9-1. To test this, M1-1 and M1-2 were
individually incubated with HLMs, HIMs, HPMs, and HRMs. Both
liver and kidney were found to be important biotransformation sites
for the formation of M9-2 and M9-1. In HLMs, the formation of M9-2
was 8 times higher than that of M9-1. In HRMs, the formation of M9-
2 was 16 times higher than that of M9-1. These observations were in
agreement with the preference in vivo. Incubations with recombinant
human UGTs and inhibition studies with selective chemical inhibitors
suggested that UGT2B7 was the major UGT isozyme catalyzing the
formation of M9-2; UGT1A4 and UGT2B7 were both important UGT
isozymes catalyzing the formation of M9-1.
M1-1 (E-3-hydroxy-apatinib) and M1-2 (Z-3-hydroxy-apatinib)
were E- and Z-isomers. Measured as AUC0–24 hour ratios at steady
state, M1-1 was 1.6 times greater than M1-2, and the sum of M1-1 and
its O-glucuronide conjugate (M9-2) was 5.87 times higher than the
sum of M1-2 and its O-glucuronide conjugate (M9-1). M1-1 in urine
and feces was also higher than M1-2. Therefore, a preference was
identified in humans for the formation of M1-1 to its Z-isomer M1-2.
However, the in vitro microsomal incubation studies and the chemical
oxidative reactions both showed a preference for the formation of the
Z-isomer M1-2. Further investigation is needed to reveal the exact
causes.
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